Last reviewed · How we verify
Nitroglycerin ointment 2%, USP
Nitroglycerin ointment 2%, USP is a Small molecule drug developed by MediQuest Therapeutics. It is currently in Phase 1 development.
Nitroglycerin ointment 2% USP is used to treat conditions such as Raynaud's Phenomenon, as indicated by ClinicalTrials.gov. The mechanism of action of nitroglycerin ointment 2% USP is unknown, according to ChEMBL.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Nitroglycerin ointment 2%, USP |
|---|---|
| Sponsor | MediQuest Therapeutics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Nitrates and Bone Turnover; Nitrates and Bone Turnover Bisphosphonate Sub-Study (PHASE3)
- MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison (PHASE1)
- MQX-503 vs Nitroglycerin Ointment: A Pharmacokinetic Comparison in Normal Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nitroglycerin ointment 2%, USP CI brief — competitive landscape report
- Nitroglycerin ointment 2%, USP updates RSS · CI watch RSS
- MediQuest Therapeutics portfolio CI
Frequently asked questions about Nitroglycerin ointment 2%, USP
What is Nitroglycerin ointment 2%, USP?
Who makes Nitroglycerin ointment 2%, USP?
What development phase is Nitroglycerin ointment 2%, USP in?
Related
- Manufacturer: MediQuest Therapeutics — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing